Compare Amgen, Inc. (AMGN) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs MINISO Group Holding Ltd — how do they compare? Amgen, Inc. trades at $412.21 (market cap $225.71B), while MINISO Group Holding Ltd trades at $12.03 (market cap $3.74B). The key difference: Amgen, Inc. is far larger — about 60.4× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (5.32%). Which is the better fit depends on your goals.
| AMGN | MNSO | |
|---|---|---|
Market Cap | $225.71B | $3.74B |
Sector | Health | Technology |
52-Week High | $417.20 | $26.63 |
52-Week Low | $271.18 | $11.30 |
Enterprise Value | $269.02B | $4.41B |
Dividend Yield | 2.42% | 5.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.
MNSO trades at $12.55, showing minimal daily movement (-0.08%). The stock exhibits neutral technical signals with bearish moving averages, trading near key support at $12. Fundamentally, the company reported strong Q1 2026 earnings that beat expectations with 28.5% revenue growth, though recent quarters showed mixed results. The company announced a HK$2 billion share repurchase program in June 2026, signaling management confidence in undervalued shares.
MNSO presents a compelling value opportunity with attractive valuation ratios (P/E 12.65, P/S 1.15) and improving profitability (2026 net margin projected at 8.98%). However, investors face risks from margin compression and volatile quarterly performance. With 75% analyst buy ratings and technical support at current levels, the stock offers upside potential but requires monitoring of execution consistency and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
